Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-03-2005 | Article

Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase

Authors: D. Xu, Z. Zhang, L. Jin, F. Chu, Y. Mao, H. Wang, M. Liu, M. Wang, L. Zhang, G. F. Gao, F. S. Wang

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2005

Abstract

In order to further the present knowledge of the emerging severe acute respiratory syndrome-associated coronavirus (SARS-CoV), 486 different specimens from 54 patients with a clinical diagnosis of SARS were investigated for the presence of viral RNA, and 314 plasma specimens of 73 patients were examined for IgM and IgG antibodies specific against SARS-CoV using an indirect ELISA. Viral RNA was detectable in 28 of the 54 patients tested. Cumulative data showed that 67 of the 73 SARS patients demonstrated seroconversion by week 5 of illness. In contrast, only 1 of 278 healthy subjects enrolled in the study was found to be positive for the IgG antibody. Coexistence of viral RNA in plasma and specific antibodies was simultaneously observed over three consecutive weeks in two critical cases. In three convalescent patients in particular, cultivable SARS-CoV was detected in stool or urine specimens for longer than 4 weeks (29–36 days). These findings suggest that SARS-CoV may remain viable in the excretions of convalescent patients.

World Health Organization (2004) Summary of probable SARS with onset of illness from 1 November 2002 to 31 July 2003. Available at: http://www.who.int/csr/sars/country/table2004_04_21/en/. Cited 8 May 2004

Tambyah PA (2004) SARS: responding to an unknown virus. Eur J Clin Microbiol Infect Dis 23:589–595

Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348:1967–1976CrossRefPubMed

Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ, SARS Working Group (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348:1953–1966CrossRefPubMed

Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattra J et al. (2003) The genome sequence of the SARS-associated coronavirus. Science 300:1399–1404

Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, Cheng VC, Chan KH, Tsang DN, Yung RW, Ng TK, Yuen KY, SARS Study Group (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319–1325CrossRef

Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksíazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 300:1394–1399

Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen BG, Peiris M, Lim W, Stohr K, Osterhaus AD (2003) Aetiology: Koch’s postulates fulfilled for SARS virus. Nature 423:240

Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY, HKU/UCH SARS Study Group (2003) Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361:1767–1772CrossRefPubMed

10.

Li G, Chen X, Xu A (2003) Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med 349:508–509

11.

Chen X, Zhou B, Li M, Liang X, Wang H, Yang G, Wang H, Le X (2004) Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis 189:1158–1163

12.

Leung GM, Chung PH, Tsang T, Lim W, Chan SK, Chau P, Donnelly CA, Ghani AC, Fraser C, Riley S, Ferguson NM, Anderson RM, Law YL, Mok T, Ng T, Fu A, Leung PY, Peiris JS, Lam TH, Hedley AJ (2004) SARS-CoV antibody prevalence in all Hong Kong patient contacts. Emerg Infect Dis 10:1653–1656

13.

Poon LL, Chan KH, Wong OK, Yam WC, Yuen KY, Guan Y, Lo YM, Peiris JS (2003) Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol 28:233–238

14.

Poon LL, Chan KH, Wong OK, Cheung TK, Ng I, Zheng B, Seto WH, Yuen KY, Guan Y, Peiris JS (2004) Detection of SARS coronavirus in patients with severe acute respiratory syndrome by conventional and real-time quantitative reverse transcription-PCR assays. Clin Chem 50:67–72

15.

Chan KH, Poon LL, Cheng VC, Guan Y, Hung IF, Kong J, Yam LY, Seto WH, Yuen KY, Peiris JS (2004) Detection of SARS coronavirus in patients with suspected SARS. Emerg Infect Dis 10:294–299

16.

Bressler AM, Nolte FS (2004) Preclinical evaluation of two real-time, reverse transcription-PCR assays for detection of the severe acute respiratory syndrome coronavirus. J Clin Microbiol 42:987–991

17.

World Health Organization (2003) PCR primers for SARS developed by WHO network laboratories [monograph on the Internet]. Available at: http://www.who.int/csr/sars/primers/en/. Cited 20 April 2003

18.

Liang WN, Mi J, Information Branch Joint Leadership Group of SARS Prevention and Control in Beijing (2003) Epidemiological features of severe acute respiratory syndrome in Beijing. Zhonghua Liu Xing Bing Xue Za Zhi 24:1096–1099

19.

Zhou XZ, Zhao M, Wang FS, Jiang TJ, Li YG, Nie WM, Zhou ZP, Wang Y, He J, Fan R, Zhao JM, Zhang XW (2003) Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area. Zhonghua Yi Xue Za Zhi 83:1018–1022

20.

Berger A, Drosten C, Doerr HW, Sturmer M, Preiser W (2004) Severe acute respiratory syndrome (SARS)-paradigm of an emerging viral infection. J Clin Virol 29:13–22

21.

Mahony JB, Petrich A, Louie L, Song X, Chong S, Smieja M, Chernesky M, Loeb M, Richardson S, Ontario Laboratory Working Group for the Rapid Diagnosis of Emerging Infections (2004) Performance and cost evaluation of one commercial and six in-house conventional and real-time reverse transcription-PCR assays for detection of severe acute respiratory syndrome coronavirus. J Clin Microbiol 42:1471–1476

22.

Xu D, Zhang Z, Chu F, Li Y, Jin L, Zhang L, Gao GF, Wang FS (2004) Genetic variation of SARS coronavirus in Beijing hospital. Emerg Infect Dis 10:789–794

23.

Li ZZ, Shen KL, Wei XM, Wang HL, Lu J, Tian H, Sun GQ, Zeng JJ, Hu YH, Zhao SY, Yin J, Feng XL, Jiang ZF, Yang YH (2003) Clinical analysis of pediatric SARS cases in Beijing. Zhonghua Er Ke Za Zhi 41:574–577

24.

Leong HN, Chan KP, Khan AS, Oon L, Se-Thoe SY, Bai XL, Yeo D, Leo YS, Ang B, Ksiazek TG, Ling AE (2004) Virus-specific RNA and antibody from convalescent-phase SARS patients discharged from hospital. Emerg Infect Dis 10:1745–1750

25.

Hsueh PR, Hsiao CH, Yeh SH, Wang WK, Chen PJ, Wang JT, Chang SC, Kao CL, Yang PC, SARS Research Group of National Taiwan University College of Medicine and National Taiwan University Hospital (2003) Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome, Taiwan. Emerg Infect Dis 9:1163–1167

26.

Xu D, Zhang Z, Wang FS (2004) SARS-associated coronavirus quasispeies in individual patients. New Engl J Med 350:1366–1367

27.

Tian W, Deng YJ, Wu QF, Wang XM, Yang L, Zhang F, Liu CH, Bao QY, Wang J, Yang H, Liu M (2004) Isolation and identification of SARS-CoV from stool of SARS patients in different phase of disease. World Chin J Digestol 12:1246–1248

Title: Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase
Authors: D. Xu
Z. Zhang
L. Jin
F. Chu
Y. Mao
H. Wang
M. Liu
M. Wang
L. Zhang
G. F. Gao
F. S. Wang
Publication date: 01-03-2005
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2005
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-005-1299-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2005

Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone

Changes in antimicrobial resistance of Escherichia coli causing urinary tract infections in hospitalized children

Molecular diagnosis of Fusobacterium necrophorum infection (Lemierre’s syndrome)

Antimicrobial resistance patterns and serotype distribution among Salmonella enterica strains in Turkey, 2000–2002

Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs

Monitoring treatment response by the hepatitis C virus core antigen assay

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials